A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)

Trial Profile

A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Duvelisib (Primary) ; Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms SYNCHRONY
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2016 Status changed from recruiting to discontinued.
    • 21 Mar 2016 Planned number of patients changed from 64 to 46 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top